Cohen & Steers Inc. (CNS)
NYSE: CNS
· Real-Time Price · USD
75.88
-0.19 (-0.25%)
At close: May 23, 2025, 3:59 PM
75.75
-0.17%
After-hours: May 23, 2025, 04:04 PM EDT
-0.25% (1D)
| Bid | 69.12 |
| Market Cap | 3.87B |
| Revenue (ttm) | 544.77M |
| Net Income (ttm) | 157.04M |
| EPS (ttm) | 3.06 |
| PE Ratio (ttm) | 24.8 |
| Forward PE | 23.51 |
| Analyst | Hold |
| Ask | 89.02 |
| Volume | 121,193 |
| Avg. Volume (20D) | 222,041 |
| Open | 74.91 |
| Previous Close | 76.07 |
| Day's Range | 75.30 - 76.56 |
| 52-Week Range | 67.09 - 110.67 |
| Beta | 1.36 |
Analyst Forecast
According to 0 analyst ratings, the average rating for CNS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+9.62%
Shares of capital market companies are trading hig...
Unlock content with
Pro Subscription
2 months ago
+2.6%
Shares of financial stocks are trading higher amid overall market strength on reports of potentially narrowed or targeted tariffs, which may be easing investor concerns.
1 month ago · businesswire.com
Alto Neuroscience to Participate in the JonesResearch Virtual CNS DayMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel pre...
2 months ago · businesswire.com
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS ForumSAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...